Next-level Dose Given in Trial of Stem Cell Therapy for Bradykinesia
IMAC Holdings has completed dosing the second group of patients in its Phase 1 clinical trial testing umbilical cord-derived mesenchymal stem cell therapy for the treatment of bradykinesia due to Parkinson’s disease. About a year ago, a first group of five patients received a low dose of the…